Dengue vaccine reaches the wet season

The first large-scale rollout of a dengue vaccine began this month across Southeast Asia, timed to the start of the wet season when the disease peaks and the hospitals fill, and the campaign is a test of everything that makes dengue a difficult target. The vaccine protects against a virus that comes in four types, that offers only temporary immunity to the types not encountered, and that turns the second infection into the dangerous one, the combination that defeated the earlier attempts and forced the current vaccine’s cautious design. The rollout, phased by age and by prior exposure, is the most careful immunization campaign the tropics have ever mounted, and its progress will be read by every country that lives with the disease.

The science of the rollout explains the caution. The vaccine’s design protects against all four serotypes, and its performance is strongest in the people who have already had a dengue infection, whose immune systems can be boosted rather than taught; the campaign therefore begins with the older children and the adults, the groups most likely to have been exposed, and defers the youngest until the safety data accumulates. The sequencing is the opposite of the usual immunization logic, where the children come first, and the reversal is the honest measure of how much the vaccine’s developers still do not know. The trials that produced the vaccine were the largest ever run for the disease, and the campaign is the first time the findings are being applied at scale.

The public health arithmetic of dengue is the background that makes the rollout urgent. The disease has been spreading with the warming world, its range has moved into latitudes that never saw it, its case counts have broken records for a decade running, and the burden falls on the countries least able to carry it, the cities of the tropics where the water storage and the waste handling create the breeding grounds that no vaccine can remove. The vaccine is not the solution to dengue; it is the reduction of the risk that the solution can be built around, and the reduction is real even at the rollout’s cautious pace. The campaign’s planners describe the vaccine as one tool among several, and the description is not modesty but accuracy: the mosquitoes that carry the disease will keep breeding, and the immunity that the vaccine confers will have to be maintained.

The rollout’s obstacles are the part that the campaign’s careful design cannot fully control. The cold chain that the vaccine requires runs through the same rainy season that the campaign is timed to exploit, the acceptance campaigns have to overcome the vaccine hesitancy that the region’s recent history has cultivated, and the surveillance systems that will judge the rollout’s success have to distinguish the vaccine’s effects from the natural variation of the disease. The teams running the campaign have rehearsed the failure modes with a thoroughness that the disease’s history justifies, and the rehearsals are the reason the rollout’s first weeks have gone smoothly, which is the kind of sentence that public health officials learn to distrust.

The wet season will be the verdict. The cases will rise across the region, as they always do, and the comparison that matters will be drawn next spring, when the data shows whether the vaccinated cohorts were admitted to the hospitals less often than the unvaccinated, whether the severe cases fell, whether the four serotypes held their ground. The campaign’s planners will spend the winter watching the same charts that the epidemiologists have watched for decades, with one difference: this year the charts will carry the first evidence of what an imperfect vaccine, deployed carefully in a difficult disease, can do. The tropics have been promised dengue control for as long as anyone can remember; this month, they received the first instalment that the science could actually deliver.